Skip to Content

Loxapine Pregnancy and Breastfeeding Warnings

Loxapine is also known as: Adasuve, Loxitane, Loxitane C, Loxitane IM

Medically reviewed on Sep 7, 2017

Loxapine Pregnancy Warnings

In rats, embryofetal toxicity has been demonstrated with doses approximately one-half of the maximum recommended human doses on a mg/m2 basis. Teratogenicity has not been demonstrated in the rat, rabbit, or dog. There are no controlled data in human pregnancy. Neonates exposed during the third trimester are at risk of developing severe and/or prolonged side effects (e.g., agitation, hyper/hypotonia, tremor, somnolence, respiratory distress, feeding disorder). The side effects have varied in severity and duration, with some neonates requiring intensive care support and prolonged hospitalization.

US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

Use is not recommended unless the benefit outweighs the risk to the fetus.

US FDA pregnancy category: C

Comment: Exposed neonates should be monitored for the signs/symptoms of extrapyramidal syndrome and/or withdrawal.

See references

Loxapine Breastfeeding Warnings

A decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother.

Excreted into human milk: Unknown
Excreted into animal milk: Yes

Comments:
-Some experts recommend that patients avoid breastfeeding for 48 hours and discard any milk produced during this interval.
-An alternate drug may be preferred, especially when breastfeeding a newborn or premature infant.

This drug is present in the milk of lactating dogs. There is no information available on the use of this drug during breastfeeding.

See references

References for pregnancy information

  1. "Product Information. Loxapine Succinate (loxapine)." Mylan Pharmaceuticals Inc, Morgantown, WV.
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  3. "Product Information. Loxitane C Oral Concentrate (loxapine)" Watson Laboratories Inc, Corona, CA.
  4. "Product Information. Adasuve (loxapine)." Teva Pharmaceuticals USA, North Wales, PA.

References for breastfeeding information

  1. "Product Information. Loxapine Succinate (loxapine)." Mylan Pharmaceuticals Inc, Morgantown, WV.
  2. "Product Information. Loxitane C Oral Concentrate (loxapine)" Watson Laboratories Inc, Corona, CA.
  3. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  4. United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL: http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT." ([cited 2013 -]):
  5. "Product Information. Adasuve (loxapine)." Teva Pharmaceuticals USA, North Wales, PA.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide